Is Tecfidera’s patent win a pyrrhic victory for Biogen?Shares in Biogen jumped last week after the company successfully defended its blockbuster MS drug Tecfidera from a Share XIs Tecfidera’s patent win a pyrrhic victory for Biogen?https://pharmaphorum.com/views-analysis-sales-marketing/tecfideras-patent-pyrrhic-victory-biogen/
Q4 results roundup 2019With the full year results season drawing to a close, Richard Staines asks who the winners were and Share XQ4 results roundup 2019https://pharmaphorum.com/sales-marketing/q4-results-roundup-2019/
Mylan reports lower than expected earningsMylan has reported lower than expected full year earnings and 2019 forecasts, thanks partly to delays in its Share XMylan reports lower than expected earningshttps://pharmaphorum.com/news/mylan-reports-lower-than-expected-earnings/
Sanofi expects growth as rare disease drugs boost earningsSanofi’s strategy of betting on new drugs and biotech acquisitions seems to be paying off, as the company Share XSanofi expects growth as rare disease drugs boost earningshttps://pharmaphorum.com/news/sanofi-expects-growth-as-rare-disease-drugs-boost-earnings/
